stroke

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and EuropeBioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH)ODD status may expedite drug candidate development and approvals…

3 months ago
Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patientsPhilips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients

Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients

February 10, 2025 Groundbreaking program that provides technology and training is reducing the impact of stroke, one of the leading…

3 months ago
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke ConferenceRecursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison…

3 months ago
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug NelonemdazGNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…

5 months ago
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug NelonemdazGNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…

5 months ago
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading PositionRapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at…

7 months ago
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading PositionRapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at…

7 months ago
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading PositionRapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at…

7 months ago